Advanced Functional Materials,
Journal Year:
2024,
Volume and Issue:
34(38)
Published: June 12, 2024
Abstract
Photoresponsive
drug
delivery
systems
(PDDSs)
have
emerged
as
a
promising
toolbox
for
delivery,
offering
precise
control
over
the
site,
duration,
and
dosage
of
light‐triggered
medication.
It
allows
controlled
release,
photo‐triggered
targeting,
diagnosis,
treatment,
improving
precision
efficacy
therapies
various
diseases.
Despite
progress
in
designing
different
PDDSs,
clinical
translation
has
been
limited
due
to
obstacles.
Herein,
this
review
article
focuses
on
three
critical
challenges
PDDSs:
1)
accumulation
at
diseased
lesions,
2)
light
irradiation,
3)
penetration
tissues.
Also,
summarizes
discusses
current
advancements
strategies
address
these
challenges.
Overall,
it
emphasizes
need
clarify
from
bench
bedside
develop
enhance
therapeutic
outcomes,
increase
compatibility
patient
compliance,
unlock
possibilities
therapies.
ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(34), P. 23497 - 23507
Published: Aug. 15, 2024
Colorectal
cancer
(CRC)
is
a
major
global
health
concern,
and
the
development
of
effective
treatment
strategies
crucial.
Enzyme
prodrug
therapy
(EPT)
shows
promise
in
combating
tumors
but
faces
challenges
achieving
sustained
expression
therapeutic
enzymes
optimal
biological
distribution.
To
address
these
issues,
fungi-triggered
situ
chemotherapeutics
generator
(named
as
SC@CS@5-FC)
was
constructed
via
oral
delivery
(5-fluorocytosine,
5-FC)
for
orthotopic
colorectal
tumor.
When
SC@CS@5-FC
targets
tumor
through
tropism
by
Nano Letters,
Journal Year:
2024,
Volume and Issue:
24(8), P. 2661 - 2670
Published: Feb. 12, 2024
Nanomaterial-assisted
chemodynamic
therapy
(CDT)
has
received
considerable
attention
in
recent
years.
It
outperforms
other
modalities
by
its
distinctive
reactive
oxygen
species
(ROS)
generation
through
a
nonexogenous
stimulant.
However,
CDT
is
limited
the
insufficient
content
of
endogenous
hydrogen
peroxide
(H2O2).
Herein,
biodegradable
MnS@HA-DOX
nanocluster
(MnS@HA-DOX
NC)
was
constructed
situ
biomineralization
from
hyaluronic
acid,
to
enlarge
ROS
cascade
and
boost
Mn2+-based
CDT.
The
acid-responsive
NCs
could
quickly
degrade
after
internalization
into
endo/lysosomes,
releasing
Mn2+,
H2S
gas,
anticancer
drug
doxorubicin
(DOX).
Fenton-like
reaction
catalyzed
Mn2+
amplified
both
DOX,
producing
mass
cytotoxic
·OH
radicals.
Through
combined
action
gas
(GT),
CDT,
chemotherapy,
oxidative
stress
would
be
synergistically
enhanced,
inducing
irreversible
DNA
damage
cell
cycle
arrest,
eventually
resulting
cancer
apoptosis.
ChemMedChem,
Journal Year:
2024,
Volume and Issue:
19(11)
Published: Feb. 24, 2024
Conventional
chemotherapy
is
insufficient
for
precise
cancer
treatment
due
to
its
lack
of
selectivity
and
inevitable
side
effects.
Targeted
drugs
have
emerged
as
a
promising
solution
treatment.
A
common
strategy
conjugate
therapeutic
agents
with
ligands
that
can
specifically
bind
tumor
cells,
providing
targeted
therapy.
Similar
the
more
successful
antibody
drug
conjugates
(ADCs),
small
molecule
(SMDCs)
are
another
class
drugs,
consisting
three
parts:
targeting
ligand,
cleavable
linker
payload.
Compared
ADCs,
SMDCs
advantages
smaller
size,
better
permeability,
simpler
preparation
process
non-immunogenicity,
making
them
alternative
ADCs.
This
review
describes
characteristics
payload
criteria
selecting
suitable
one.
We
also
discuss
recently
reported
list
some
entered
clinical
trials.
Advanced Functional Materials,
Journal Year:
2024,
Volume and Issue:
34(38)
Published: June 12, 2024
Abstract
Photoresponsive
drug
delivery
systems
(PDDSs)
have
emerged
as
a
promising
toolbox
for
delivery,
offering
precise
control
over
the
site,
duration,
and
dosage
of
light‐triggered
medication.
It
allows
controlled
release,
photo‐triggered
targeting,
diagnosis,
treatment,
improving
precision
efficacy
therapies
various
diseases.
Despite
progress
in
designing
different
PDDSs,
clinical
translation
has
been
limited
due
to
obstacles.
Herein,
this
review
article
focuses
on
three
critical
challenges
PDDSs:
1)
accumulation
at
diseased
lesions,
2)
light
irradiation,
3)
penetration
tissues.
Also,
summarizes
discusses
current
advancements
strategies
address
these
challenges.
Overall,
it
emphasizes
need
clarify
from
bench
bedside
develop
enhance
therapeutic
outcomes,
increase
compatibility
patient
compliance,
unlock
possibilities
therapies.
